Sanofi in discussions to sell a controlling stake in Opella Paris, . Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of ...

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, . Sanofi advances its ambition to protect ...

Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. We’re proud to be premium ...

If you are a healthcare professional or a patient seeking to report an adverse event, please call 1-800-265-7927 to speak with a Sanofi Medical Information agent or click here to visit Sanofi Medical ...

John Sundy is currently Chief Medical Officer and Head of Research and Development at Seicmic Therapeutic, a machine learning immunology company and is Adjunct Professor of Medicine in the Division of ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion ...

24 abstracts for Dupixent, including 4 oral presentations, highlight impact of targeting interleukin-4 (IL4) and interleukin-13 (IL13) across atopic dermatitis (AD), prurigo nodularis (PN) and chronic ...

Paris, France, and Houston, Texas, September 12, 2024. As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi has entered into an exclusive licensing ...